Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Other

Trial to Compare the SherpaPak™ Device vs Cold Storage

Organ Transplant

Enrolled (actual)
20
Serious AEs
15.0%
Results posted
Feb 2025
Primary outcome: Primary: Absence of Moderate to Severe Primary Graft Dysfunction (Left or Right Ventricle) — 10; 10 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
SherpaPak™ Device (Device); Cold Storage (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cedars-Sinai Medical Center
Primary completion
Aug 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Absence of Moderate to Severe Primary Graft Dysfunction (Left or Right Ventricle)
10; 10
PRIMARY
30-day Post-transplant Survival
10; 9
PRIMARY
Freedom From 30-day Ischemic Reperfusion Injury
10; 8
PRIMARY
Freedom From 30-day Biopsy Proven Rejection
9; 8
PRIMARY
Freedom From 30-day Any-treated Rejection
9; 8
SECONDARY
Cardiac Index
3.1; 3.5
SECONDARY
Cardiac Output
5.6; 6.5
SECONDARY
Mean Arterial Pressure
79; 83
SECONDARY
Pulmonary Arterial Pressure
25; 22
SECONDARY
Vasoactive-Inotropic Score
264.1; 395.3
SECONDARY
Hospital Length of Stay
15.1; 21.1
SECONDARY
Acute Cellular Rejection
5; 3
SECONDARY
1R
5; 3
SECONDARY
Antibody Mediated Rejection
1; 1
SECONDARY
pAMR 1
1; 1

Summary

The Investigator's are doing this study to see which method of organ preservation leads to better outcomes for donated hearts. There are two methods of organ preservation. The first method is the use of cold storage. With this method, the donor heart is stored in preservation fluid within bags that are then placed on ice and transported in a cooler. This is the usual method for transporting donor hearts. This is also known as "standard of care." The second method is the use of the SherpaPak™ Cardiac Transport System. With this method, the donor heart is kept at a steady, consistent temperature throughout transportation. This method is not typically used for transporting donor hearts. The study will include up to 20 people in total.

Eligibility Criteria

Inclusion Criteria

  • Any sex/gender, 18 years of age or older listed for primary heart transplant.
  • Subjects must be willing and be capable of understanding the purpose and risks of the study and must sign a statement of informed consent OR consent of a legally authorized representative of a cognitively impaired individual will be obtained before the cognitively impaired individual may be included in research.
  • Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information
  • Subjects must receive and accept a non-local donor offer (from Northern California, Arizona, Nevada or farther geographies)

Exclusion Criteria

  • Re-do heart transplant
  • Multi-organ transplant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05194514). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search